PredilifeFRA:0GA -5.88%29 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates FRA:0GA with a GF Score™ of 29/100 and a GF Value™ of €18.80 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Predilife ranks better than 99.48% on this metric.
The historical rank and industry rank for Predilife's Days Payable or its related term are showing as below:
FRA:0GA'
s Days Payable Range Over the Past 10 Years
Min: 1412.55 Med: 3743.36 Max: 16874.23
Current: 15751.15
During the past 10 years, Predilife's highest Days Payable was 16874.23. The lowest was 1412.55. And the median was 3743.36.
FRA:0GA's Days Payable is ranked better than 99.48% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.09
vs FRA:0GA: 15751.15
Predilife's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Predilife Days Payable Related Terms
Predilife Days Payable Historical Data
* Premium members only.
The historical data trend for Predilife's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0GA vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Predilife's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predilife Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Predilife's Days Payable distribution charts can be found below:
* The bar in red indicates where Predilife's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Predilife's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predilife (FRA:0GA) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Predilife and its competitors. Over the past decade, Predilife's Days Payable has ranged from 1,412.55 to 16,874.23. According to the industry distribution chart, Predilife ranks #1 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Predilife's Days Payable too high?
Predilife's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,412.55 to a high of 16,874.23. Based on the distribution chart, Predilife ranks #1 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Predilife has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Predilife's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Predilife ranks #1 out of 191 companies for Days Payable. This places Predilife in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 65.09. Historically, Predilife's own Days Payable has ranged from 1,412.55 to 16,874.23 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.09, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Predilife and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Predilife's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predilife stock overvalued right now?
Based on GuruFocus' analysis, Predilife (FRA:0GA) is currently considered Possible Value Trap. The stock's GF Value™ is €18.80, compared to a current price of €2.08 — trading 88.9% below its estimated fair value. The current Days Payable is 0.00. Predilife's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Predilife (FRA:0GA), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Predilife (FRA:0GA) Overvalued in 2026?
Based on GuruFocus' analysis, Predilife stock appears to be undervalued.
The current stock price of €2.08 is trading 88.9% below its estimated GF Value™ of €18.80.
GuruFocus considers Predilife to be Possible Value Trap.
Key valuation signals for FRA:0GA:
Days Payable: 0.00
GF Value™: €18.80 vs. price of €2.08 (88.9% below fair value)
No single metric tells the full story. See the FRA:0GA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Predilife SA develops solutions for predictive medicine, combining medical techniques (genetic tests, medical imaging) and mathematical models with a large amount of statistical data, which allows each individual to define their risk profile for the occurrence of various serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.
29GF Score
Get the complete analysis for FRA:0GA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0GA has been successfully added to your 
